20. Feb, 2022
Ivermectin - je to užitečný lék v prevenci progrese onemocnění COVID-19 do závažného průběhu?
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
Steven Chee Loon Lim, MRCP; Chee Peng Hor, MSc; Kim Heng Tay, MRCP; Anilawati Mat Jelani, MMed; Wen Hao Tan, MMed; Hong Bee Ker, MRCP; Ting Soo Chow, MRCP; Masliza Zaid, MMed; Wee Kooi Cheah, MRCP; Han Hua Lim, MRCP; Khairil Erwan Khalid, MRCP; Joo Thye Cheng, MRCP; Hazfadzila Mohd Unit, MRCP; Noralfazita An, MMed; Azraai Bahari Nasruddin, MRCP; Lee Lee Low, MRCP; Song Weng Ryan Khoo, MRCP; Jia Hui Loh, MRCP; Nor Zaila Zaidan, MMed; Suhaila Ab Wahab, MMed; Li Herng Song, MD; Hui Moon Koh, MClinPharm; Teck Long King, BPharm; Nai Ming Lai, MRCPCH; Suresh Kumar Chidambaram, MRCP; Kalaiarasu M. Peariasamy, MSc; for the I-TECH Study Group
IMPORTANCE Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. OBJECTIVE To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease.
INTERVENTIONS Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging
CONCLUSIONS AND RELEVANCE In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19
JAMA Intern Med. doi:10.1001/jamainternmed.2022.0189 Published online February 18, 2022.